Chronic Inflammatory Demyelinating Polyneuropathy
Conditions
Keywords
Actimyo, Accelerometry, Daily living
Brief summary
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Detailed description
On each visit, participants will undergo a clinical examination with MRC sum score, a mISS score and a I-RODS score. They will perform few tests 6-minutes walk test (6MWT), a myogrip measurement, and a 9 Hole Peg Test (9HPT) and will answer to some questionaires (mISS, INCAT and PGIC). Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Interventions
DEVICEActimyo
Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Sponsors
SYSNAV
Centre Hospitalier Régional de la Citadelle
Centre Hospitalier Universitaire de Liege
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2. * Treated with IVIg (≤1g/kg/3-8week) * Clinically Stable disease for 3 months (according to treating physician opinion). * No treatment withdrawal failure within 1 year * Age over 18 years
Exclusion criteria
* Significant cognitive or communication disorders * Surgery or serious traumatic injury ≤ 6 months * Non ambulant patient * Current participation to a therapeutic trial * Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy * Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment * Pregnancy or breastfeeding * Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 95th centile of stride velocity | 1 year | 95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo) in real-life (meter per second). |
| 50th centile of stride velocity | 1 year | 50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo) in real-life (meter per second). |
| 95th centile of stride length | 1 year | 95th centile of stride length obtained with a magneto-inertial sensor (Actimyo) in real-life (meter). |
| 50th centile of stride length | 1 year | 50th centile of stride length obtained with a magneto-inertial sensor (Actimyo) in real-life (meter). |
Countries
Belgium
Contacts
Primary ContactLaurie Medard
Backup ContactMargaux Poleur, Dr
Outcome results
None listed